Late-stage functionalization with strain-release warheads enables tunable covalent inhibition · Z. P. Shultz et al.
原文开头
Full article and list of author affiliations: https://doi.org/10.1126/ science.adx7219 Zachary P. Shultz, Ansar Lee-Sam, Yun-Pu Chang, Luxin Sun, Dylan Grassie, Alessio Gabellini, Kyle Pedretty, Thomas Scattolin, Victoria Izumi, Bin Fang, Samer Sansil, Ramu Kakumanu, Lukasz Wojtas, John Koomen, Ernst Schönbrunn, Andrii Monastyrskyi, Derek Duckett, Justin M. Lopchuk* INTRODUCTION: Covalent drugs are transforming targeted therapy by forming durable bonds with disease-driving proteins, yet most rely on a narrow set of reactive groups, particularly acrylamides. These conventional approaches, although effective, can lead to off-target interactions and restrict broader application by their limited structural design. Expanding covalent drug design beyond these established chemotypes is essential to improve both selectivity and therapeutic performance. …
摘自《科学》(Science)第393卷 第6809期 · 2026年7月23日,Z. P. Shultz et al.。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。